• Increase font size
  • Default font size
  • Decrease font size

Subscriber Only Content

More News

Breaking News

More News

RSS Subscription

MIT Receives License Amendment Approval; FTC Sues to Block Omnicare's Bid

Below is a look at some of the headlines for companies that made news in the healthcare sector on January 27, 2012.
Read more...
 

Ut oh! Lpath Suspends Dosing of iSONEP in Clinical Trials

FDA CalendarShares of Lpath, Inc. rose over 40% since we helped break their story to biotech investors who have been paying close attention since the firm announced a partnership with Pfizer to develop a wet AMD drug candidate called iSONEP.  Yesterday evening came news that the firm has suspended-- at least temporarily-- the dosing of patients in its PEDigree and Nexus trials and share prices are taking a beating in early trading.
Read more...
 

Cornerstone Announces New Analysis Shows Lower Mortality Rates; MelApp for iPhone Application Receives Record Downloads

Below is a look at some of the headlines for companies that made news in the healthcare sector on January 26, 2012.
Read more...
 

Another Catalyst for Protalix

FDA CalendarProtalix BioTherapeutics, Inc. (AMEX:PLX)  gave traders another forward-looking catalyst after they announced that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held February 8-10 in San Diego, California.
Read more...
 

Updated: Scorecard and Technical Bounce Fishing Under $5

FDA CalendarThe formulas for our technical and fundamental analysis scans which look for stocks under $5 that are showing great signs for bouncing off lows are hitting with good levels of accuracy in one of the most volatile sectors: biotechnology.
Read more...
 

Advaxis Reports Preliminary Data from Phase 2 Trial; Neurocrine Announces Fast Track Designation For VMAT2

Below is a look at some of the headlines for companies that made news in the healthcare sector on January 25, 2012.
Read more...
 

Updated: Neurocrine granted Fast Track designation; Continues creating value for investors

noneNeurocrine Biosciences, Inc. (NASDAQ:NBIX) announced on Wednesday that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of neuroleptic-induced tardive dyskinesia.
Read more...
 

Depomed Announces Initiation of Phase 2 Clinical Study; Aeterna Zentaris Announces "At-the-Market" Issuance Program

Below is a look at some of the headlines for companies that made news in the healthcare sector on January 24, 2012.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 275
about 5 hours ago MIT Receives License Amendment Approval; FTC Sues to Block Omnicare's Bid: Below is a look at some of the headli... http://t.co/T67IpBMr
about 15 hours ago Ut oh! Lpath Suspends Dosing of iSONEP in Clinical Trials: Shares of Lpath, Inc. rose over 40% since we helped b... http://t.co/H6NgHIAA
about 15 hours ago $LPTN shares drop over 30% after they suspend trials: http://t.co/7Kx9UXIR
about 15 hours ago Idenix Pharmaceuticals ($IDIX) down after Stifel Nicolaus downgrades shares to Sell from Hold
about 16 hours ago Amex confirms resolution of iBio's ($IBIO) listing deficiency. In Nov. Exchange said iBio was not in compliance with Section 1003(a)(iv).
about 1 day ago Stock Market Today: Stocks Fall Amid Mixed Economic And Earnings Reports - http://t.co/QwRjtSq5
about 1 day ago Cornerstone Announces New Analysis Shows Lower Mortality Rates; MelApp for iPhone Application Receives Record Do... http://t.co/r2dz00DO
about 1 day ago CEL-SCI ($CVM) $5.76M Registered Direct raise - Shares fall back a nickle in heavy trading - Warrants priced at $.50 http://t.co/5riTY3QJ

navigation

Free Phone Trade Alerts